Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PFKFB3 | Q16875 | 8/20 | 0.53 |
| ▸ | PFKFB4 | Q16877 | 7/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | EPM2A | O95278 | 1/20 | 0.38 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.38 |
| ▸ | CMA1 | P23946 | 4/20 | 0.38 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.36 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1742182 | 0.85 | PFKFB3 (0.51) | PFKFB3PFKFB4NPSR1L3MBTL1EPM2A | |
| SCHEMBL787935 | 0.84 | PFKFB3 (0.50) | PFKFB3PFKFB4NPSR1L3MBTL1EPM2A | |
| SCHEMBL787942 | 0.81 | CMA1 (0.51) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL2226181 | 0.81 | NPSR1 (0.60) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| Hydrochloric Acid SCHEMBL6712744 | 0.79 | NPSR1 (0.59) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL787895 | 0.78 | PFKFB3 (0.57) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL806148 | 0.78 | L3MBTL1 (0.47) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL6027735 | 0.77 | L3MBTL1 (0.39) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL788255 | 0.77 | L3MBTL1 (0.46) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 | |
| SCHEMBL3684890 | 0.77 | MEN1 (0.43) | PFKFB3PFKFB4NPSR1L3MBTL1CMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1450806-B1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB PUBL (SE) | 2009-04-29 | — | — | EP | disclosed |
| EP-1696915-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | Pfizer, Inc. (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AGOURON PHARMACEUTICALS, INC. | 2005-07-07 | — | — | US | disclosed |
| WO-2005060963-A1 | BENZENESULFONYLAMINO-PYRIDIN-2-YL DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11-BETA-HSD-1) FOR THE TREATMENT OF DIABETES AND OBESITY | PFIZER INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1450806-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2004-09-01 | — | — | EP | disclosed |
| US-20030166663-A1 | Use | BIOVITRUM AB (SE) | 2003-09-04 | — | — | US | disclosed |
| WO-2003039547-A1 | USE OF SULFONAMIDE DERIVATIVES IN THE TREATMENT OF OBESITY OR FOR THE REDUCTION OF FOOD INTAKE | BIOVITRUM AB (SE) | 2003-05-15 | — | — | WO | disclosed |
| EP-1228066-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032646-A2 | SULFONAMIDE DERIVATIVES | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148631-A1 | Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B11, HSD11B2 | PFKFB3 3931/4885PFKFB4 3867/4885NPSR1 1936/4885 |
| US-20030166663-A1 | Use | SULT2A1, SULT1A1, SLC5A1 | PFKFB3 2345/4885PFKFB4 2318/4885NPSR1 76/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.